Gilead Sciences

This early-stage study tests a new oral drug called GS-4571 for weight management. Researchers will give single or multiple doses to healthy people, non-diabetic obese individuals, and non-obese people with type 2 diabetes. The main goals are to see how the drug moves through the…

This study tests whether tenofovir alafenamide (TAF) is safe and effective for children and teens with chronic hepatitis B. About 150 participants will receive either TAF or a placebo. The goal is to see if the drug can lower the virus in the blood and to find the right dose for …

This study tests a long-acting HIV medicine called lenacapavir in teens and children (weighing at least 35 kg) who have tried other HIV drugs before. The goal is to see if the drug is safe, tolerable, and works well when combined with other HIV medications. Participants will rece…

This study tests whether a new drug combination (sacituzumab govitecan plus pembrolizumab) works better than standard treatments for people with triple negative breast cancer that still remains after surgery and pre-surgery therapy. About 1,514 adults will take part. The goal is …

This early-phase study tests a new drug called denikitug, alone or with another cancer drug (zimberelimab), in adults with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety, find the best dose, and see if the drug shrinks tum…

This study tests a drug called sacituzumab govitecan against standard treatments for people with extensive stage small cell lung cancer that has already been treated once. About 695 participants will be randomly assigned to receive either the study drug or usual care. The main go…

This study provides access to the drug bulevirtide for people with chronic hepatitis delta virus (HDV) infection who have compensated liver cirrhosis. The goal is to control the virus and manage the disease, not to cure it. Participants must have confirmed HDV and meet specific l…

This study tests a different dose and schedule of the drug sacituzumab govitecan in people with advanced triple-negative breast cancer (TNBC). The goal is to see if this new approach is safe and works better at shrinking tumors or slowing cancer growth. About 100 adults with TNBC…

This early-phase study aims to find a safe starting dose of the drug sacituzumab govitecan for people with advanced solid tumors who also have moderate liver impairment. About 30 participants will receive the drug to monitor side effects and how the drug moves through the body. T…

This early-phase study tests a new drug called GS-5319 in adults with advanced solid tumors that lack a gene called MTAP. The main goals are to check the drug's safety, find the best dose, and see how the body processes it. About 178 participants whose cancer has not responded to…

This study tests new combinations of drugs in people with non-small-cell lung cancer. It includes three groups: those with newly diagnosed advanced cancer, those whose cancer has returned after treatment, and those with early-stage cancer that can be surgically removed. The goal …

This study tests a drug called seladelpar in 318 adults with primary biliary cholangitis (PBC) and compensated cirrhosis. The goal is to see if it can prevent serious events like death, liver transplant, or complications from liver disease. Participants will receive either the dr…

This study tests a new two-drug combination (bictegravir/lenacapavir) for children and teens with HIV-1 whose virus is already under control with complex daily meds. About 75 participants aged 2 to 17 will receive the study drug to see if it is safe and how the body processes it.…

This study tests a new drug called GS-4321 for chronic hepatitis delta, a serious liver infection. First, healthy volunteers will help determine safe dosing. Then, people with the infection will receive the drug to see if it reduces virus levels and improves liver health. The goa…

This study tests an experimental drug called tilpisertib fosmecarbil (GS-5290) in 176 adults with moderate to severe ulcerative colitis. Participants will receive either the drug or a placebo for 12 weeks to see if it helps reduce symptoms like diarrhea, bleeding, and inflammatio…

This study tests a drug called sacituzumab govitecan in people with advanced bladder cancer that has spread and cannot be removed by surgery. The goal is to see if the drug can shrink tumors or slow the cancer's growth. About 827 adults are taking part, and the drug is given alon…

This early-stage study tests a new experimental HIV medicine, GS-3242, in 30 people living with HIV-1. The goal is to see how safe it is, how the body processes it, and how well it lowers the amount of virus in the blood over 11 days. Participants must have a certain level of vir…

This early-stage study tests a new drug called GS-2121, given alone or with another drug (zimberelimab), in adults with advanced solid tumors that have not responded to standard treatments. The main goal is to check safety and find the best dose. About 154 participants will take …

This study follows 3,000 people in the US who choose lenacapavir (a long-acting injection) to prevent HIV. Researchers want to see how well participants stick with the treatment over a year. The goal is to understand how this new PrEP option works in everyday clinics, not just in…

This study tests a new way to prevent HIV using an injection given just once a year. The drug, lenacapavir, is given as a shot into the muscle. Researchers want to see if it is safe and how well it stays in the body over 12 months. About 350 people at risk for HIV will take part.

This early-stage study tests the safety and how the body handles a new drug called GS-0151 in 75 adults with rheumatoid arthritis. Participants receive multiple doses of the drug or a placebo. The goal is to find out if the drug is safe and well-tolerated, not yet to prove it wor…